Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Kerbel, Robert S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Bevacizumab; Drug resistance; Endothelial progenitor cells; Metronomic chemotherapy; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MONOCLONAL ANTIBODY DC101; PACLITAXEL; SORAFENIB; SUNITINIB; TRASTUZUMAB; UFT; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HYPOXIA; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

EID: 72049110823     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70271-1     Document Type: Article

References (70)

1. Kerbel R.S. Tumor Angiogenesis. N Engl J Med 358 (2008) 2039-2049
2. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; in press.
3. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 312 (2006) 1171-1175
4. Chan A. Antiangiogenic therapy for metastatic breast cancer: current status and future directions. Drugs 69 (2009) 167-181
5. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
6. Miles D., Chan A., Romieu G., et al. Randomized, double-blind placebo-controlled, phase III study of bevacizumab (BV) with docetaxel (D) or D with placebo (PL) as 1st-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc Am Soc Clin Oncol 26 (2008) LBA1011
7. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
8. Kindler H.L., Friberg G., Singh D.A., Locker G., Nattam S., Kozloff M., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 (2005) 8033-8040
9. Keating G.M., and Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69 (2009) 223-240
10. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
11. Moreno-Aspitia A., Morton R.F., Hillman D.W., Lingle W.L., Rowland Jr. K.M., Wiesenfeld M., et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 27 (2009) 11-15
12. Cacheux W., Boisserie T., Staudacher L., Vignaux O., Dousset B., Soubrane O., et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 19 (2008) 1659-1661
13. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26 (2008) 1810-1816
14. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Anti-angiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; in press.
15. Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 (2000) 306-314
16. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 (2008) 206-220
17. Norden A.D., Young G.S., Setayesh K., Muzikansky A., Klufas R., Ross G.L., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70 (2008) 779-787
18. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 (2008) 592-603
19. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3 (2006) 24-40
20. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
21. Shaked Y., and Kerbel R.S. Antiangiogenic strategies on defense: blocking rebound by the tumor vasculature after chemotherapy. Cancer Res 67 (2007) 7055-7058
22. Shaked Y., Ciarrocchi A., Franco M., Lee C.R., Man S., Cheung A.M., et al. Therapyinduced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006) 1785-1787
23. Shaked Y., Henke E., Roodhart J., Mancuso P., Langenberg M., Colleoni M., et al. Rapid chemotherapy-induced surge in endothelial progenitor cells: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14 (2008) 263-273
24. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13 (1991) 31-36
25. Miller K.D., Sweeney C.J., and Sledge Jr. G.W. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19 (2001) 1195-1206
26. Sweeney C.J., Miller K.D., Sissons S.E., Nozaki S., Heilman D.K., Shen J., et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61 (2001) 3369-3372
27. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D., et al. Continuous lowdose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 (2000) R15-R24
28. Browder T., Butterfield C.E., Kraling B.M., Marshall B., O'Reilly M.S., and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
29. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
30. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57 (1997) 963-969
31. Casanovas O., Hicklin D., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
32. Glade Bender J., Cooney E.M., Kandel J.J., and Yamashiro D.J. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 7 (2004) 289-300
33. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., and Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295 (2002) 1526-1528
34. Steeg P.S. Angiogenesis inhibitors: motivators of metastasis?. Nat Med 9 (2003) 822-823
35. Bottaro D.P., and Liotta L.A. Cancer: Out of air is not out of action. Nature 423 (2003) 593-595
36. Peinado H., and Cano A. A hypoxic twist in metastasis. Nat Cell Biol 10 (2008) 253-254
37. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116 (2006) 2610-2621
38. Dean M., Fojo T., and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 5 (2005) 275-284
39. Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26 (2008) 5326-5334
40. Ellis L.M., and Haller D.G. Bevacizumab beyond progression: does this make sense?. J Clin Oncol 26 (2008) 5313-5315
41. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
42. Norden-Zfoni A., Desai J., Manola J., Beaudry P., Force J., Maki R., et al. Bloodbased biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13 (2007) 2643-2650
43. Ebos J.M.L., Lee C.R., Christensen J.G., Mutsaers A.J., and Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with anti-tumor efficacy. Proc Natl Acad Sci USA 104 (2007) 17069-17074
44. Suzuki M., Mose E., Galloy C., and Tarin D. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol 171 (2007) 682-692
45. Kerbel R.S., and Kamen B.A. Antiangiogenic basis of low-dose metronomic chemotherapy. Nat Rev Cancer 4 (2004) 423-436
46. Munoz R., Man S., Shaked Y., Lee C., Wong J., Francia G., et al. Highly efficacious nontoxic treatment for advanced metastatic breast cancer using combination UFT- cyclophosphamide metronomic chemotherapy. Cancer Res 66 (2006) 3386-3391
47. du Manoir J.M., Francia G., Man S., Mossoba M., Medin J.A., Viloria-Petit A., et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab (Herceptin®) in human breast cancer xenografts. Clin Cancer Res 12 (2006) 904-916
48. Francia G., Emmenegger U., Lee C.R., Shaked Y., Folkins C., Mossoba M., et al. Long term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-hCG choriogonadotropin secreting tumor cell lines. Mol Cancer Ther 7 (2008) 3452-3459
49. Hanahan D., Bergers G., and Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105 (2000) 1045-1047
50. Bertolini F., Paul S., Mancuso P., Monestiroli S., Gobbi A., Shaked Y., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63 (2003) 4342-4346
51. F ̈ urstenberger G., von Moos R., Lucas R., Thürlimann B., Senn H.-J., Hamacher J., et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy or primary breast cancer. Br J Cancer 94 (2006) 524-531
52. Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7 (2005) 101-111
53. Shaked Y., Emmengger U., Man S., Cervi D., Bertolini F., Ben-David Y., et al. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106 (2005) 3058-3061
54. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23 (2005) 939-952
55. Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L., et al. Phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian cancer. A trial of the California, Chicago and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 26 (2007) 76-82
56. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer: clinical and biological activity. J Clin Oncol 26 (2008) 4899-4905
57. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
58. Colleoni M., Rocca A., Sandri M.T., Zorzino L., Masci G., Nole F., et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13 (2002) 73-80
59. Bottini A., Generali D., Brizzi M.P., Fox S.B., Bersiga A., Bonardi S., et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24 (2006) 3623-3628
60. Emmenegger U., Man S., Shaked Y., Francia G., Wong J.W., Hicklin D.J., et al. A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64 (2004) 3994-4000
61. Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 (2003) 1431-1439
62. Natori T., Sata M., Washida M., Hirata Y., Nagai R., and Makuuchi M. G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 297 (2002) 1058-1061
63. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450 (2007) 825-831
64. Ng S.S.W., Sparreboom A., Shaked Y., Lee C., Man S., Desai N., et al. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res 12 (2006) 4331-4338
65. Bocci G., Francia G., Man S., Lawler J., and Kerbel R.S. Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100 (2003) 12917-12922
66. Hamano Y., Sugimoto H., Soubasakos M.A., Kieran M., Olsen B.R., Lawler J., et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64 (2004) 1570-1574
67. Orlando L., Cardillo A., Ghisini R., Rocca A., Balduzzi A., Torrisi R., et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6 (2006) 225
68. Kolata G., and Pollack A. Costly cancer drug offers hope, but also a dilemma. New York Times (2008 Jul 6)
69. Jubb A.M., Oates A.J., Holden S., and Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6 (2006) 626-635
70. Schneider B.P., Wang M., Radovich M., Sledge G.W., Badve S., Thor A., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26 (2008) 4672-4678